Argentina approves AstraZeneca / Oxford Covid vaccine


Published on: Amended:

Buenos Aires (AFP)

Argentina followed Britain to become the second country to authorize the coronavirus vaccine developed by pharmaceutical company AstraZeneca and the University of Oxford, the government said on Wednesday.

Argentina signed a production agreement for the vaccine, which was added to an emergency registry for a year, the national drug administration said.

“The product has an acceptable benefit / risk ratio,” the administration said in a statement.

The vaccine can be stored, transported and handled under normal refrigerated conditions, and is therefore cheaper and easier to administer than other jabs developed by Pfizer / BioNTech and Moderna that require freezing.

Argentina and Mexico have reached an agreement to produce the vaccine and distribute it in Latin America.

This is the third Covid vaccine to be approved in Argentina after the Pfizer / BioNTech and Sputnik V vaccinations.

The South American country on Tuesday began administering Sputnik V, which has been criticized for its deployment despite the lack of clinical trials.

Argentina has acquired 300,000 doses of Sputnik V and an additional 19 million are expected to arrive in January and February.

However, the government has not yet reached an agreement with the American pharmaceutical giant Pfizer on the acquisition of its vaccine.

Argentina has recorded more than 43,000 deaths and more than 1.6 million cases of coronavirus among its 44 million people.

The government of President Alberto Fernandez has announced plans to purchase 51 million doses of the vaccine in total.


Please enter your comment!
Please enter your name here